image description

Tag: MD

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

  First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […] Read More

Less Risk and Greater Efficacy in Pediatric Lupus Nephritis Treatment

There is no doubt about it. The research into the mechanisms of pediatric lupus nephritis conducted by Elena Hsieh, MD, at the University of Colorado Anschutz Medical Campus, is driven by her genuine concern for the wellbeing of children—and a lifelong passion for science. With her new grant from the Lupus Research Alliance, Dr. Hsieh—who […] Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] Read More

Watch Webcast Video: Redefining Lupus Trials Amid COVID-19 and Beyond

Videotape of 8.24.20 Learn from Lupus Zoom Webcast Ensuring the clinical trial process is accommodating for participants has always been the goal. However, COVID-19 has forced industry, research organizations, doctors, and patients to think twice about the process and its impact on high-risk populations including people with lupus who are immunocompromised. In light of COVID-19, […] Read More

NIH Leader and LRA Board Member Key Author on Promising COVID-19 Vaccine

August 13, 2020 The Lupus Research Alliance (LRA) is encouraged by a promising animal study in the New England Journal of Medicine co-authored by Robert Seder, MD, Chief of the Cellular Immunology Section in the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) […] Read More

Lupus and COVID-19:What You Need to Know Webcast on Video

April 3, 2020 The Lupus Research Alliance (LRA) hosted a live webcast April 2, 2020 on COVID-19 for people with lupus that you won’t want to miss – so click here to view the full video recording. The webast addressed the most frequently asked questions doctors are hearing from people with lupus, put the hydroxychloroquine […] Read More

Letter from LRA to Top U.S. Health Officials

  April 12, 2020 Today, the Lupus Research Alliance (LRA) Scientific Advisory Board Chair Dr. Gary Koretzky emailed top federal health officials a strong letter calling attention to concerns about availability of hydroxychloroquine for patients with systemic lupus erythematosus. The letter was addressed to:  Alex M. Azar II, JD, Secretary, Health and Human Services; Stephen […] Read More

New Awardees Announced by the Lupus Research Program that Advocates Helped Create

April 1, 2020 Thirteen new applications for promising scientific studies were just recommended for funding through the Lupus Research Program (LRP) within the Department of Defense! The $5 million in awards for Fiscal Year 2019 brings the total to $15 million over three years. The dedicated Lupus Research Program was first established in 2017 under […] Read More